Cellomics (Pittsburgh, PA, USA) has named Dan Calvo president and CEO. Mr. Calvo was most recently vice president of worldwide sales and service at PerkinElmer Life Sciences.
Ed Chait has been appointed CEO of Spectral Genomics (Houston, TX, USA). Dr. Chait was previously CEO of PharmaCore, and before that was senior vice president, business and technology development at Intergen Company.
Anthony A. DiTonno has been named CEO of NeurogesX (San Carlos, CA, USA). He joined the company as president last April after serving as executive vice president of marketing and sales at Enteric Medical Technologies. Former CEO Howard Palefsky will remain as chairman.
Affinium Pharmaceuticals (Toronto, ON, Canada) has announced the appointment of Charles 'Bucky' Grier to its board of directors. Dr. Grier is a director at GSK Ventures, and was most recently director, scientific licensing in worldwide business development for GlaxoSmithKline.
Miguel Angel Izquierdo has been appointed director of the clinical research department at PharmaMar (Madrid, Spain). Dr. Izquierdo joined the company in October 2002 as director of clinical oncology. He replaces Jose Maria Saro, who has left the company. Taking over for Dr. Izquierdo as director of clinical oncology is Jose Antonio Lopez.
FibroGen (S. San Francisco, CA, USA) has announced the appointment of Claire J. Lockey as vice president of regulatory affairs. Ms. Lockey joins FibroGen from Titan Pharmaceuticals where she was also vice president of regulatory affairs.
Exelixis (S. San Francisco, CA, USA) has announced the election of Frank McCormick to the company's board of directors. Dr. McCormick, who founded and served as chief scientific officer at Onyx Pharmaceuticals, is currently director of the University of California, San Francisco Comprehensive Cancer Center, and is the David A. Wood Professor of Tumor Biology and Cancer Research in the Department of Microbiology and Immunology at UCSF.
Peter Mueller has been appointed chief scientific officer and senior vice president, drug discovery and innovation at Vertex Pharmaceuticals (Cambridge, MA, USA). He joins Vertex from Boehringer Ingelheim Pharmaceuticals, where he served as senior vice president, R&D.
Evotec OAI (Hamburg, Germany) has announced that Bernard Questier has been named chief business officer. Mr. Questier joins the company from Ventana Medical Systems, where he was responsible for most of the company's business outside the United States.
Novavax (Columbia, MD, USA) has announced that Nelson M. Sims has been named president and CEO, succeeding Mitchell J. Kelly. Mr. Sims joins the company after 28 years at Eli Lilly and Company, where he served, among other positions, as president of Eli Lilly Canada and executive director of strategic alliance management. Mr. Kelly, who is also CEO of Anaconda Capital Management, will continue to serve as a director on Novavax's board.
Nucleonics (Malvern, PA, USA) has named Robert J. Towarnicki president and CEO. Mr. Towarnicki was president and CEO of Cell Pathways prior to that company's merger with OSI Pharmaceuticals in June.
Bernd Wetzel, formerly head of worldwide research and nonclinical development at Boehringer Ingelheim, has been named to the supervisory board of Direvo Biotech (Cologne, Germany).
Robert S. Whitehead has been named president, CEO and a member of the board of Prestwick Pharmaceuticals (Washington, DC, USA). Most recently, he served as senior vice president and chief business officer of ZymoGenetics.
Seattle Genetics (Seattle, WA, USA) has named Douglas E. Williams chief scientific officer and executive vice president, R&D. He will continue to be a member of the company's board of directors, a position he has held since May 2001. Dr. Williams was previously executive vice president and chief technology officer at Immunex, and he became senior vice president and Washington site leader after Immunex's merger with Amgen. Most recently, he has been head of health and strategic development for Genesis Research & Development, a New Zealand-based biotech company.
Rights and permissions
About this article
Cite this article
People. Nat Biotechnol 21, 1105 (2003). https://doi.org/10.1038/nbt0903-1105